Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540663 | 0.87 | IDO1 (0.41) | — | |
| SCHEMBL7214541 | 0.82 | USP2 (0.39) | LTA4HMEN1KMT2ATAAR1MAPKAPK2 | |
| SCHEMBL5921850 | 0.81 | KIF11 (0.48) | CYP19A1CYP11B2 | |
| SCHEMBL6502611 | 0.80 | POLB (0.51) | MEN1KMT2ACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3403146 | 0.80 | CYP11B1 (0.41) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6189088 | 0.80 | PTGDR2 (0.36) | MAPK14CYP19A1PTGDR2 | |
| SCHEMBL5184111 | 0.80 | CYP19A1 (0.61) | MEN1KMT2ACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6504970 | 0.80 | CYP19A1 (0.39) | KMT2ARAB9ACYP19A1 | |
| SCHEMBL8309987 | 0.80 | LMNA (0.42) | KMT2ARAB9ACYP19A1CYP11B1 | |
| SCHEMBL20521097 | 0.79 | ALDH1A1 (0.42) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010046215-A2 | DIAZA-INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| EP-2136640-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngeta Participations AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008132434-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-11-06 | — | — | WO | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1278520-A4 | DIARYL PIPERIDYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | MERCK & CO INC (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003024447-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1278520-A1 | DIARYL PIPERIDYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | Merck & Co., Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1131318-A1 | PROCESS FOR MAKING 5-SUBSTITUTED PYRAZOLES USING DITHIETANES | G.D. SEARLE & CO. (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1112265-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001034150-A1 | ALIPHATIC AMINE SUBSTITUTED PIPERIDYL DIARYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | MERCK & CO., INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| CN-1261885-A | 2-substituted 4, 5-diarylimidazoles | NOVARTIS AG (CH) | 2000-08-02 | — | — | CN | disclosed |
| WO-2000031072-A1 | PROCESS FOR MAKING 5-SUBSTITUTED PYRAZOLES USING DITHIETANES | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000017192-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
| EP-0863757-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| EP-0863757-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0686156-A1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | LTA4H 825/4885MEN1 4508/4885KMT2A 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.